Day 2 Recap: Fall Clinical 2025

To stay informed with the latest conference insights, follow us on social media and subscribe to receive our eNewsletters.

Envudeucitinib Demonstrates Sustained Efficacy and Safety in Moderate to Severe Plaque Psoriasis

Data from Fall Clinical 2025 detailed the results from the phase 2 STRIDE and ongoing open-label extension studies demonstrating the efficacy and safety of envudeucitinib, a selective TYK2 inhibitor.

Brad Glick, DO, MPH, FOACD, Highlights New Standards in AD Management

The AHEAD guidelines promote a new treatment standard for atopic dermatitis, emphasizing near-complete skin clearance and itch relief.

Icotrokinra Shows Durable Efficacy for PsO, Including Hard-to-Treat Areas, in 1-Year ICONIC-TOTAL Trial

New data from Johnson & Johnson's ICONIC-TOTAL study reveals icotrokinra's promising long-term efficacy and safety for treating challenging plaque psoriasis.

James Del Rosso, DO, Celebrates a Quarter Century of Dermatology Innovation in Las Vegas

Del Rosso recounts the meeting’s evolution and its consistent mission to bridge science and practice.

How GEP Testing Refines Risk Stratification in Melanoma and High-Risk cSCC

At Fall Clinical, Nguyen outlined how gene expression profile testing complements traditional staging systems—helping clinicians better identify melanoma and cSCC patients at the highest risk for recurrence.

Baricitinib Achieves Significant Hair Regrowth in Pediatric AA

At 52 weeks, the data presented at Fall Clinical showed that 64.8% and 63.3% of adolescents on baricitinib 4 mg achieved significant eyebrow and eyelash regrowth, respectively.

Our editors are on site and ready to gather your insights, both as a presenter or as an attendee! Reach out to us at DTEditor@mmhgroup.com for the opportunity to speak with one of our editors. Stay tuned to Dermatology Times all weekend for exclusive conference coverage and expert insights.